S N Jonas1, I Izbudak2, A A Frazier3, D M Harrison4. 1. From the Department of Radiology (S.N.J., A.A.F.), University of Maryland Medical Center, Baltimore, Maryland samueljonas@umm.edu. 2. Department of Radiology/Neuroradiology (I.I), Johns Hopkins University, Baltimore, Maryland. 3. From the Department of Radiology (S.N.J., A.A.F.), University of Maryland Medical Center, Baltimore, Maryland. 4. Department of Neurology, University of Maryland School of Medicine (D.M.H.), Baltimore, Maryland.
Abstract
BACKGROUND AND PURPOSE: Preliminary research has demonstrated that postgadolinium 3D-FLAIR MR imaging at 7T may be a valuable tool for detecting abnormal meningeal enhancement and inflammation in MS; however, researchers have not systematically investigated its longitudinal persistence. We hypothesized that persistence of meningeal enhancement in MS varies on the basis of pattern of enhancement as well as demographic and clinical factors such as treatment status, disease phenotype, and disability score. MATERIALS AND METHODS: Thirty-one subjects with MS were prospectively scanned before and after intravenous contrast administration at 2 time points, approximately 1 year apart. Fifteen subjects in the cohort were scanned at another time approximately 1 year later. Foci of enhancement were categorized into 4 subtypes: subarachnoid spread/fill, subarachnoid nodular, vessel wall, and dural foci. We reviewed follow-up scans to determine whether foci changed between time points and then compared persistence with demographic and clinical variables. RESULTS: Persistence ranged from 71% to 100% at 1 year and 73% to 100% at 2 years, depending on the enhancement pattern. Subarachnoid spread/fill and subarachnoid nodular subtypes persisted less often than vessel wall and dural foci. Persistence was not significantly different between those on/off treatment and those with progressive/nonprogressive disease phenotypes. The number of persisting foci was significantly different in subjects with/without increasing Expanded Disability Status Scale scores (median, 12 versus 7.5, P = .04). CONCLUSIONS: Longitudinal persistence of meningeal enhancement on 3D-FLAIR at 7T in MS varies by pattern of enhancement and correlates with worsening disability; however, it is not significantly different in those on/off treatment or in those with progressive/nonprogressive disease phenotypes.
BACKGROUND AND PURPOSE: Preliminary research has demonstrated that postgadolinium 3D-FLAIR MR imaging at 7T may be a valuable tool for detecting abnormal meningeal enhancement and inflammation in MS; however, researchers have not systematically investigated its longitudinal persistence. We hypothesized that persistence of meningeal enhancement in MS varies on the basis of pattern of enhancement as well as demographic and clinical factors such as treatment status, disease phenotype, and disability score. MATERIALS AND METHODS: Thirty-one subjects with MS were prospectively scanned before and after intravenous contrast administration at 2 time points, approximately 1 year apart. Fifteen subjects in the cohort were scanned at another time approximately 1 year later. Foci of enhancement were categorized into 4 subtypes: subarachnoid spread/fill, subarachnoid nodular, vessel wall, and dural foci. We reviewed follow-up scans to determine whether foci changed between time points and then compared persistence with demographic and clinical variables. RESULTS: Persistence ranged from 71% to 100% at 1 year and 73% to 100% at 2 years, depending on the enhancement pattern. Subarachnoid spread/fill and subarachnoid nodular subtypes persisted less often than vessel wall and dural foci. Persistence was not significantly different between those on/off treatment and those with progressive/nonprogressive disease phenotypes. The number of persisting foci was significantly different in subjects with/without increasing Expanded Disability Status Scale scores (median, 12 versus 7.5, P = .04). CONCLUSIONS: Longitudinal persistence of meningeal enhancement on 3D-FLAIR at 7T in MS varies by pattern of enhancement and correlates with worsening disability; however, it is not significantly different in those on/off treatment or in those with progressive/nonprogressive disease phenotypes.
Authors: P Flachenecker; T Kümpfel; B Kallmann; M Gottschalk; O Grauer; P Rieckmann; C Trenkwalder; K V Toyka Journal: Mult Scler Date: 2002-12 Impact factor: 6.312
Authors: Martina Absinta; Irene C M Cortese; Luisa Vuolo; Govind Nair; Manori P de Alwis; Joan Ohayon; Alessandro Meani; Vittorio Martinelli; Roberta Scotti; Andrea Falini; Bryan R Smith; Avindra Nath; Steven Jacobson; Massimo Filippi; Daniel S Reich Journal: Neurology Date: 2017-03-10 Impact factor: 9.910
Authors: Nicholas J Tustison; Brian B Avants; Philip A Cook; Yuanjie Zheng; Alexander Egan; Paul A Yushkevich; James C Gee Journal: IEEE Trans Med Imaging Date: 2010-04-08 Impact factor: 10.048
Authors: Daniel M Harrison; Kevin Y Wang; Julie Fiol; Kerry Naunton; Walter Royal; Jun Hua; Izlem Izbudak Journal: J Neuroimaging Date: 2017-05-02 Impact factor: 2.486
Authors: José P Marques; Tobias Kober; Gunnar Krueger; Wietske van der Zwaag; Pierre-François Van de Moortele; Rolf Gruetter Journal: Neuroimage Date: 2009-10-09 Impact factor: 6.556
Authors: Markus C Kowarik; Sabine Cepok; Johann Sellner; Verena Grummel; Martin S Weber; Thomas Korn; Achim Berthele; Bernhard Hemmer Journal: J Neuroinflammation Date: 2012-05-16 Impact factor: 8.322
Authors: Chris H Polman; Stephen C Reingold; Brenda Banwell; Michel Clanet; Jeffrey A Cohen; Massimo Filippi; Kazuo Fujihara; Eva Havrdova; Michael Hutchinson; Ludwig Kappos; Fred D Lublin; Xavier Montalban; Paul O'Connor; Magnhild Sandberg-Wollheim; Alan J Thompson; Emmanuelle Waubant; Brian Weinshenker; Jerry S Wolinsky Journal: Ann Neurol Date: 2011-02 Impact factor: 10.422
Authors: Owain W Howell; Elena Katharina Schulz-Trieglaff; Daniele Carassiti; Steven M Gentleman; Richard Nicholas; Federico Roncaroli; Richard Reynolds Journal: Neuropathol Appl Neurobiol Date: 2015-05-02 Impact factor: 8.090
Authors: Mehrnaz Ighani; Samuel Jonas; Izlem Izbudak; Seongjin Choi; Alfonso Lema-Dopico; Jun Hua; Erin E O'Connor; Daniel M Harrison Journal: Mult Scler Date: 2019-10-01 Impact factor: 6.312
Authors: N Bergsland; D Ramasamy; E Tavazzi; D Hojnacki; B Weinstock-Guttman; R Zivadinov Journal: AJNR Am J Neuroradiol Date: 2019-03-14 Impact factor: 3.825
Authors: Whitney M Freeze; Merel van der Thiel; Jeroen de Bresser; Catharina J M Klijn; Ellis S van Etten; Jacobus F A Jansen; Louise van der Weerd; Heidi I L Jacobs; Walter H Backes; Susanne J van Veluw Journal: Neuroimage Clin Date: 2020-10-02 Impact factor: 4.881